| 研究課題/領域番号 |
23H02104
|
|---|
| 配分区分 | 補助金 |
|---|
| 研究機関 | 富山大学 |
|---|
研究代表者 |
Suresh Awale 富山大学, 学術研究部薬学・和漢系, 准教授 (00377243)
|
|---|
| 研究分担者 |
藤井 努 富山大学, 学術研究部医学系, 教授 (60566967)
|
|---|
| 研究期間 (年度) |
2023-04-01 – 2028-03-31
|
| キーワード | pancreatic cancer / antiausterity / napthylisoquinolines / antitumor agents / in vivo / chemical biology |
|---|
| 研究実績の概要 |
We investigated naphthylisoquinoline alkaloids as a potential new chemotherapeutic agent against pancreatic cancer. In 2023, we screened over 200 naphthylisoquinoline alkaloids against MIA PaCa-2 pancreatic cancer cell line and identified promising candidates. Study on structure-activity relationship to guide future development has been achieved. We've also explored the molecular mechanisms of selected compounds, which could lead to a deeper understanding of their anti-cancer effects. In addition, we also discovered novel naphthoquinones as potent antiausterity agents against human PANC-1 pancreatic cancer cells and published the results. Our findings hold promise for the development of novel, targeted treatments for this aggressive disease.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We've screened a vast library of NIQs, and identified several potent candidates with selective cytotoxicity against pancreatic cancer cells in nutrient-deprived conditions at nanomolar concentration range. We're now investigating the molecular mechanisms of these promising compounds.
|
| 今後の研究の推進方策 |
We'll extensively study the effects of our active NIQ compounds on cancer cell morphology, migration, colony formation, and chemotaxis. We'll also investigate their ability to block survival pathways within the pancreatic tumor microenvironment, aiming to enhance cancer cell death. Finally, we'll evaluate the efficacy of selected NIQs against orthotopic MIA PaCa-2 tumors, both as single agents and in combination with gemcitabine (GEM).
|
